Chart 2. Studies evaluating chemotherapy in advanced small bowel adenocarcinoma.
| Reference | Regimen | Number of patients | Response rate (%) | Progression- free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|
| Crawley et al.(35) | 5FU | 8 | 37 | 7.8 | 13.0 |
| Locher et al.(36) | 5FU + cisplatin | 20 | 21 | 8.0 | 14.0 |
| Gibson et al.(37) | 5FU + doxorubicin + MMC | 38 | 18 | 5.0 | 8.0 |
| Zaanan et al.(38) | FOLFOX | 48 | 34 | 6.9 | 17.8 |
| LV5FU2 | 10 | 0 | 7.7 | 13.5 | |
| LV5FU2 +cisplatin | 19 | 30 | 6.0 | 9.6 | |
| FOLFIRI | 16 | 9 | 4.8 | 10.6 | |
| Overman et al.(39) | 5FU + cisplatin | 29 | 41 | 8.7 | 14.8 |
| 5FU without cisplatin | 41 | 17 | 3.9 | 12.0 | |
| Overman et al.(40) | Capecitabine + oxaliplatin | 30 | 52 | 11.3 | 20.0 |
| Zaanan et al.(41) | FOLFIRI (second line) | 28 | 20 | 3.2 | 10.5 |
5FU: 5-fluorouracil; MMC: mitomycin C; FOLFOX: 5-fluorouracil/leucovorin/oxaliplatin; LV5FU2: 5-fluorouracil/leucovorin; FOLFIRI: 5-fluorouracil/leucovorin/irinotecan. Reprinted from: Aparicio et al.,(10) with permission from Elsevier.